The Euro--lupus project: epidemiology of systemic lupus erythematosus in Europe, vol.18, pp.869-74, 2009. ,
,
, American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis, Arthritis Care Res, vol.64, issue.6, pp.797-808, 2012.
Effect of Renal Disease on the Standardized Mortality Ratio and Life Expectancy of Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatism, vol.65 ,
Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions, Lupus. avr, vol.19, issue.5, pp.557-74, 2010. ,
, , p.12
Outcomes in African Americans and Hispanics with lupus nephritis, Kidney International, vol.69, issue.10, pp.1846-51, 2006. ,
Value of a Complete or Partial Remission in Severe Lupus Nephritis, Clin J Am Soc Nephrol, 2008. ,
Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis. Lupus, vol.26, pp.1139-1187, 2017. ,
Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis & Rheumatism, vol.50, pp.2559-68 ,
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long--term followup of patients in the Euro--Lupus Nephritis Trial: Early Response to Treatment Predicts Good Outcome in Lupus Nephritis. Arthritis & Rheumatism [Internet]. déc, vol.50, pp.3934-3974, 2004. ,
Predictors of Long--Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro--Lupus Nephritis Cohort. Arthritis & Rheumatology, vol.67, pp.1305-1318 ,
A proteinuria cut--off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial, Lupus Science & Medicine, vol.2, issue.12, pp.123-000123, 2015. ,
Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus, Revue Médicale Suisse, vol.64, pp.2677-86, 2012. ,
Immunosuppressive therapy in lupus nephritis: The Euro--Lupus Nephritis Trial, a randomized trial of low--dose versus high--dose intravenous cyclophosphamide. Arthritis & Rheumatism, vol.46, pp.2121-2152 ,
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA--EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, The American Journal of the Medical Sciences, vol.346, pp.1771-82, 2012. ,
Severe lupus nephritis: the predictive value of a ? 50% reduction in proteinuria at 6 months, Nephrol Dial Transplant. sept, vol.28, issue.9, pp.2313-2321, 2013. ,
Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis, Lupus, vol.11, issue.3, pp.152-60, 2002. ,
Factors associated with poor outcomes in patients with lupus nephritis, Lupus, vol.14, issue.11, pp.890-895, 2005. ,
Factors predictive of outcome in severe lupus nephritis, American Journal of Kidney Diseases, vol.35, issue.5, pp.904-918, 2000. ,
, Prognosis in proliferative lupus nephritis: the role of socio--economic status and race/ethnicity. Nephrology Dialysis Transplantation, vol.18, pp.2039-2085, 2003.
Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review, Arthritis Res Ther, vol.19, issue.1, p.238, 2017. ,
Long--term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine, Lupus, vol.14, issue.4, pp.265-72, 2005. ,
Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long--term followup of a cohort of 145 patients participating in randomized controlled studies, Arthritis Rheum. avr, vol.46, issue.4, pp.995-1002, 2002. ,
Excess atherosclerosis in systemic lupus erythematosus,--A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls, PLoS ONE, vol.12, issue.4, p.174572, 2017. ,
Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis, Am J Kidney Dis. janv, vol.43, issue.1, pp.28-36, 2004. ,
,
La néphropathie lupique : le point en, 2014. ,
,
,
Observations on the occurrence of exacerbations in clinical course of systemic lupus erythematosus. The Journal of Medical Investigation, vol.55, pp.112-121, 2008. ,
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, vol.71, pp.1771-82, 2012. ,
American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis, Arthritis Care Res, vol.64, issue.6, pp.797-808 ,
Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis & Rheumatism, vol.50, pp.2559-68 ,
The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe, vol.18, pp.869-74, 2009. ,
Baseline characteristics of a multiethnic lupus cohort: PROFILE ,
Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups, Lupus, vol.6, issue.3, pp.248-53, 1997. ,
Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis, Lupus, vol.11, issue.3, pp.152-60 ,
Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions, Lupus. avr, vol.19, issue.5, pp.557-74, 2010. ,
Demographic differences in the development of lupus nephritis: a retrospective analysis, The American Journal of Medicine ,
,
Antihistone and anti-double-stranded deoxyribonucleic acid antibodies are associated with renal disease in systemic lupus erythematosus, Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial: Early Response to Treatment Predicts Good Outcome in Lupus Nephritis. Arthritis & Rheumatism [Internet]. déc, vol.50, pp.165-73, 2004. ,
Anti-C1q Antibody is Associated with Renal and Cutaneous Manifestations in Asian Indian Patients with Systemic Lupus Erythematosus, J Clin Diagn Res. mars, vol.11, issue.3, pp.39-42, 2017. ,
Systemic lupus erythematosus in North American Indians: a population based study, J Rheumatol. août, vol.27, issue.8, pp.1884-91, 2000. ,
Effect of Renal Disease on the Standardized Mortality Ratio and Life Expectancy of Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatism, vol.65, pp.2154-60 ,
Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients, vol.82, p.299, 2003. ,
Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group, Am J Kidney Dis. mai, vol.85, issue.3, pp.904-918, 2000. ,
Value of a Complete or Partial Remission in Severe Lupus Nephritis, Clin J Am Soc Nephrol, 2008. ,
The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. Seminars in Arthritis and Rheumatism, vol.3, pp.77-95 ,
Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls, PLoS ONE, vol.12, issue.4, p.174572, 2017. ,
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention, vol.7, p.12, 2018. ,
,
, Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide, Kidney International, vol.57, issue.1, pp.258-64, 2000.
Outcome of relapse in lupus nephritis: Roles of reversal of renal fibrosis and response of inflammation to therapy, Kidney International, vol.61, issue.6, pp.2176-86, 2002. ,
Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome, vol.12, pp.692-698, 2003. ,
Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis, Ann Rheum Dis. mars, vol.75, issue.3, pp.526-557, 2016. ,
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited, vol.2, pp.241-50 ,
Segmental and Global Subclasses of Class IV Lupus Nephritis Have Similar Renal Outcomes, Journal of the American Society of Nephrology, vol.23, issue.1, pp.149-54 ,
The prognosis and pathogenesis of severe lupus glomerulonephritis, Nephrology Dialysis Transplantation, vol.23, issue.4, pp.1298-306, 2008. ,
Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system, Kidney International, vol.77, pp.820-829 ,
Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions, Kidney International, vol.83, issue.4, pp.715-738, 2013. ,
Collapsing glomerulopathy associated lupus in a black female with homozygous APOL1 mutation, Lupus, vol.21, issue.1, pp.1459-62, 2012. ,
Apolipoprotein L1 Risk Variants Associate with Systemic Lupus Erythematosus-Associated Collapsing Glomerulopathy, Journal of the American Society of Nephrology [Internet]. 1 mai, vol.24, issue.5, pp.722-727, 2013. ,
Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus, Arthritis Research & Therapy, vol.64, issue.8, p.202, 2012. ,
Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research, Arthritis Res Ther, vol.17, issue.1, pp.487-90, 2015. ,
Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis, Clin Exp Immunol. avr, vol.184, issue.1, pp.11-19, 2016. ,
Utility of urinary transferrin and ceruloplasmin in patients with systemic lupus erythematosus for differentiating patients with lupus nephritis, Reumatol Clin. 9 mars, 2018. ,
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs, N Engl J Med. 6 mars, vol.314, issue.10, pp.614-623, 1986. ,
Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only, Arthritis Rheum. août, vol.34, issue.8, pp.945-50, 1991. ,
,
, Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial, Ann Intern Med, vol.125, issue.7, pp.549-57, 1996.
Treatment of lupus nephritis: a meta-analysis of clinical trials, Am J Kidney Dis. févr, vol.29, issue.2, pp.193-202, 1997. ,
Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials, Am J Kidney Dis. févr, vol.43, issue.2, pp.197-208, 2004. ,
,
, Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism, p.14
, , vol.46, pp.2121-2152, 2018.
Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis, Chin Med J. mai, vol.115, issue.5, pp.705-714, 2002. ,
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group, N Engl J Med, vol.343, issue.16, pp.1156-62, 2000. ,
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis, N Engl J Med, vol.353, issue.21, pp.2219-2247, 2005. ,
Long-Term Study of Mycophenolate Mofetil as Continuous Induction and Maintenance Treatment for Diffuse Proliferative Lupus Nephritis, vol.4, pp.1076-84 ,
Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis, Journal of the American Society of Nephrology, vol.20, issue.1, pp.1103-1115, 2009. ,
Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis, Nephrology, vol.10, issue.5, pp.504-514 ,
Sequential Therapies for Proliferative Lupus Nephritis, The New England Journal of Medicine, vol.10, 2004. ,
Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis, New England Journal of Medicine, vol.365, issue.17, pp.1886-95, 1920. ,
Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Annals of the Rheumatic Diseases, vol.69, pp.2083-2092, 2010. ,
Remission of refractory lupus nephritis with a protocol including rituximab, Lupus, vol.12, issue.10, pp.783-790, 2003. ,
Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone, Scand J Rheumatol, vol.33, issue.6, pp.423-430, 2004. ,
Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis, Mod Rheumatol, vol.17, issue.2, pp.92-99, 2007. ,
A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for ,
, Maintenance Therapy in Diffuse Lupus Nephritis over Four Years, Clinical Journal of the American Society of Nephrology, vol.1, issue.12, pp.925-957, 2006.
Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial, Am J Kidney Dis. févr, vol.57, issue.2, pp.235-279, 2011. ,
Multitarget therapy for induction treatment of lupus nephritis: a randomized trial, Ann Intern Med. 6 janv, vol.162, issue.1, pp.18-26, 2015. ,
Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis, Lupus. juill, vol.19, issue.8, pp.935-975, 2010. ,
Long-term outcomes-mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases, Nephrol Dial Transplant. déc, vol.25, issue.12, pp.3939-3987, 2010. ,
A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: design of the LPSG trial, Int J Artif Organs, vol.14, issue.10, pp.639-685, 1991. ,
A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group, N Engl J Med. 21 mai, vol.326, issue.21, pp.1373-1382, 1992. ,
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis & Rheumatism ,
, The ACCESS Trial Group, Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study: Abatacept in Lupus Nephritis. Arthritis & Rheumatology, vol.64, pp.3096-104, 2014.
, Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month
, , vol.66, pp.379-89
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids, Nephrology Dialysis Transplantation, vol.24, issue.12, pp.3717-3740, 2009. ,
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Annals of the Rheumatic Diseases, vol.72, pp.1280-1286 ,
High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients, Nephrol Dial Transplant, vol.10, issue.9, pp.1620-1628, 1995. ,
Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network, Kidney Int. avr, vol.51, issue.4, pp.1188-95, 1997. ,
Outcomes in African Americans and Hispanics with lupus nephritis, Kidney International, vol.69, issue.10, pp.1846-51, 2006. ,
Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity, Nephrology Dialysis Transplantation, vol.18, issue.1, pp.2039-2085, 2003. ,
Factors associated with poor outcomes in patients with lupus nephritis, Lupus, vol.14, issue.11, pp.890-895, 2005. ,
Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone, Lupus, 2003. ,
, , vol.12, pp.287-96
Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization, Am J Med. nov, vol.83, issue.5, pp.877-85, 1987. ,
Risk factors to predict the development of chronic kidney disease in patients with lupus nephritis, Lupus, vol.26, issue.11, pp.1139-1187, 2017. ,
Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis, Am J Kidney Dis. janv, vol.43, issue.1, pp.28-36, 2004. ,
Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review, Arthritis Res Ther, vol.19, issue.1, p.238, 2017. ,
Effect of long-term normalization of serum complement levels on the course of lupus nephritis, The American Journal of Medicine, vol.87, issue.2, p.80687 ,
Factors affecting outcome and prognosis in membranous lupus nephropathy, Nephrol Dial Transplant, vol.17, issue.1, pp.1771-1779, 2002. ,
Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis, Clinical Kidney Journal [Internet]. 1 avr, vol.11, issue.2, pp.207-225, 2018. ,
Histological predictors of renal outcome in lupus nephritis: the importance of tubulointerstitial lesions and scoring of glomerular lesions, Lupus. août, vol.27, issue.9, pp.1455-63, 2018. ,
Renal outcomes in mixed proliferative and membranous lupus nephritis (Class III/IV + V): A long-term observational study, Mod Rheumatol, vol.26, issue.6, pp.908-921, 2016. ,
Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int, vol.68, pp.2288-97, 2005. ,
Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices, Kidney International, vol.93, issue.4, p.30859 ,
Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis, Kidney Int. août, vol.76, issue.3, pp.307-324, 2009. ,
Utility of a repeat renal biopsy in lupus nephritis: a single centre experience, Nephrol Dial Transplant. 1 mars, vol.33, issue.3, pp.507-520, 2018. ,
The Pathogenesis and Therapeutic Implications of ,
, Tubulointerstitial Inflammation in Human Lupus Nephritis. Semin Nephrol. sept, vol.35, issue.5, pp.455-64, 2015.
Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis, Arthritis Rheum. juill, vol.56, issue.7, pp.2362-70, 2007. ,
Predictive power of the second renal biopsy in lupus nephritis: Significance of macrophages, Kidney International ,
Severe lupus nephritis: the predictive value of a ? 50% reduction in proteinuria at 6 months, Nephrol Dial Transplant. sept, vol.28, issue.9, pp.2313-2321, 2013. ,
Predictors of Long-Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro-Lupus Nephritis Cohort. Arthritis & Rheumatology, vol.67, pp.1305-1318 ,
A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial, Lupus Science & Medicine, vol.2, issue.12, pp.123-000123, 2015. ,
Ten Common Mistakes in the Management of Lupus Nephritis, American Journal of Kidney Diseases, vol.63, issue.4, pp.667-76, 2014. ,
Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care & Research [Internet]. 1 mars, vol.63, pp.351-358, 2011. ,
Comparison of Alternative Primary Outcome Measures for Use in Lupus Nephritis Clinical Trials: Outcome Measures for Lupus Nephritis. Arthritis & Rheumatism, vol.65, pp.1586-91 ,
Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies, Arthritis Rheum. avr, vol.46, issue.4, pp.995-1002, 2002. ,
Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine, Lupus, vol.14, issue.4, pp.265-72, 2005. ,
Factors associated with relapse of lupus nephritis: A single center study of 249 cases, Saudi J Kidney Dis Transpl. déc, vol.28, issue.6, pp.1349-55, 2017. ,
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis & Rheumatism, vol.54, pp.3284-90 ,
Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Annals of the Rheumatic Diseases, vol.12, pp.821-825 ,